Bimekizumab

比奇珠单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameBimekizumab
Drug Alias Name比吉利珠单抗Bimekizumab-bkzx比美吉珠单抗BIMZELXBimzelx +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPalmoplantar pustulosis +[16] 
Global Approved IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing
Approved Indications in ChinaSpondylitis, Ankylosing
Original Approved Country/TerritoryEU
Original Approved Date2021/08/20
Country/TerritoryCzechiaBelgiumBulgaria +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesUcb Australia Pty LtdUcb Canada IncUcb Biopharma Srl +[11] 
Inactive CompaniesUcb Celltech
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPalmoplantar pustulosis +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC21
Related LinksWikipediaDrugBankKEGG